【摘要】

摘要: 目的 利培酮与阿立哌唑对阿尔茨海默病伴精神障碍患者疗效及糖脂代谢的影响。
方法 将128例阿尔茨海默病伴精神障碍患者随机分为利培酮组63例和阿立哌唑组65例。利培酮组以口服利培酮2-4mg，每日一次；阿立哌唑组以口服阿立哌唑10-20mg，每日一次；分别于治疗前和治疗3月后，使用简易智能精神状态表(MMSE)评分和阿尔茨海默病评价表-认知分量表(ADAS-cog)评分评价患者临床疗效，以及以及不良反应发生率；并比较治疗前和治疗3月后的空腹血糖、总胆固醇和甘油三酯的变化。
结果 治疗后，利培酮组与阿立哌唑组MMSE评分显著升高(p<0.05)，ADAS-cog评分显著降低(p<0.05)，两组治疗后评分相比无统计学意义(p>0.05)；治疗后，利培酮组患者血糖指标显著升高(p<0.05)，阿立哌唑组改变无统计学意义(p>0.05)，利培酮组患者治疗后血糖指标较阿立哌唑组显著升高(p<0.05)；治疗后，利培酮组与阿立哌唑组患者血脂指标显著升高(p<0.05)，利培酮组患者治疗后血脂指指标较阿立哌唑组显著升高(p<0.05)。
结论 利培酮和阿立哌唑均能用于阿尔茨海默病伴精神障碍患者的治疗，且能引起糖脂代谢异常，其中阿立哌唑对糖脂代谢的影响相对较小。

【Abstract】

Abstract Objective: To investigate the effect of risperidone and aripiprazole on the clinical efficacy and glucose/lipid metabolism in the treatment of Alzheimer disease with mental disorders.
Methods: A total of 128 patients of Alzheimer disease with mental disorders in our hospital from Jan. 2014 to Dec. 2015 were enrolled in the study, which were randomly divided into risperidone group (63 cases) and aripiprazole group (65 cases). The risperidone group were received 2-4mg risperidone oral, qn, and the aripiprazole group were received 10-20mg aripiprazole oral, qn. The easy-mental state table (MMSE) score, Alzheimer disease assessment form- cognitive subscale (ADAS-cog) score and glucose/lipid metabolism indexes were determined before and after 3 month treatment.
Results: After treatment, the MMSE scores in risperidone group and aripiprazole group were significantly increased (p<0.05), and the ADAS-cog scores in the two groups were significantly decreased (p<0.05). There was no statistical difference between the two groups (p>0.05). After treatment, the blood glucose in risperidone group was significantly increased (p<0.05), but no statistical difference in aripiprazole group (p>0.05), and the blood glucose in risperidone group was significantly higher than that in aripiprazole group (p>0.05). After treatment, the tota cholesterol and triglyceride in risperidone group and aripiprazole group were significantly increased (p<0.05), and the tota cholesterol and triglyceride in risperidone group was significantly higher than that in aripiprazole group (p>0.05).
Conclusion  : Risperidone and aripiprazole could be used for the treatment of Alzheimer disease with mental disorders. They both caused abnormal glucose and lipid metabolism, and the effect of aripiprazole was relatively mild.